Big Pharma's KRAS G12D Bet: $2.13B Deal Spawns Intensified Cancer Therapy Market

Merck (MSD) has in-licensed the rights to a KRAS G12D inhibitor developed by China's Cybreon Therapeutics for $2.13 billion, including a $400 million upfront payment.

This is one of several large-scale bets big pharma companies have made on candidates whose efficacy and safety in humans have not yet been confirmed.

The KRAS G12D mutation is considered one of the most difficult targets to develop drugs against due to its lack of structural weaknesses. However, new drug design technologies are spurring competition in therapeutics.

Other companies, including Bayer, Johnson & Johnson (J&J), and Eli Lilly and Company, are also developing KRAS G12D inhibitors or pan-KRAS agents that target multiple mutations simultaneously.